Ready to sell
your patents?

We help patent owners prepare sale opportunities and help buyers share focused acquisition requirements. IIPLA reviews potential fit and coordinates relevant discussions under separately agreed terms.

Patent owners, companies, universities, authorized advisers and prospective buyers may enquire. An IIPLA membership or public listing is not required.

Yes. Begin with contact details and a short portfolio or acquisition summary. Public patent references and supporting information can follow after the first review.

Where available, include patent or application numbers, titles, legal owner, jurisdictions, family members, status and any known licences or restrictions.

Existing licences, security interests, co-ownership or other commitments may affect a transaction. They do not automatically prevent review, but should be disclosed before diligence.

The current brokerage intake focuses on patent sales and acquisitions. Broader licensing, enforcement, development or technology-transfer work requires a separate scope.

The IIPLA team reviews the information, clarifies the objective and decides whether there is a basis for a focused follow-up. Submitting alone does not authorize outreach.

Screening organizes stated ownership, public patent status, territories, known restrictions and alignment with the relevant technology or acquisition brief.

An agreed package may include an asset schedule, non-confidential teaser, family and territory summary, commercial expectations and disclosed restrictions.

Outreach is targeted to relevant relationships and patent-market contacts, subject to agreed disclosure permissions. It is not a public listing or mass mailing.

No. A category match only supports screening. Patent scope, restrictions, price expectations and current buyer interest still require review.

Timing depends on information quality, portfolio complexity, buyer response and diligence. No sale or timetable is guaranteed, and the parties may pause or revise the approach.

A sale transfers ownership of the patent rights identified in signed transaction documents. The parties must define the exact patents, applications and related rights included.

Yes. An individual patent or a larger portfolio may be reviewed. The number of assets alone does not determine fit or value.

Yes. Identify the specific assets to include, related family members and any exclusions so the proposed grouping can be reviewed.

Sellers may state an expectation or discuss it after review. Any formal valuation is separate specialist work, and the owner decides whether an offer is acceptable.

Yes, for scope review. Identify the relevant countries, family members and filing status. An enquiry does not create U.S. rights or preserve filing deadlines.

Potentially. Existing licences and restrictions may affect transferable rights, price or required consents and should be disclosed before detailed review.

Not automatically. The transaction documents must define any assets beyond the identified patent rights; company equity, products, source code and trade secrets are separate.

Fees, commission and payment responsibility must be set out in a separate written engagement. The enquiry form itself creates no payment obligation.

The written engagement should define which proceeds attract commission and when payment becomes due, including any deferred or conditional consideration.

Any assessment, preparation, representation, specialist or transaction cost must be disclosed and agreed before the related work begins.

No. Submission creates no representation or exclusivity. Any exclusive or non-exclusive appointment requires a separate written agreement.

A buyer may request one, but it is not automatic. The owner must separately agree the assets, duration, milestones and release conditions.

Yes. Existing mandates, prior introductions and potential conflicts should be disclosed. Your chosen counsel can advise on transaction documents.

A buyer may request ownership records, prosecution history, maintenance status, licence or security documents, disputes and technical support material.

The form does not create an NDA. Use public or non-confidential information initially, then agree recipients, permitted uses and a secure channel before sensitive disclosure.

The patent owner does. IIPLA may coordinate discussions, but an expression of interest or indicative price is not a guaranteed closing.

The parties and their advisers agree the asset schedule, price, payment mechanics, conditions and assignment documents. Signed terms govern payment and transfer.

The sale and brokerage agreements govern any surviving payment, reporting, commission or document obligations. You remain free to decline an offer subject to signed commitments.